相似文献
1
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones.
Antimicrob Agents Chemother. 1990 Nov;34(11):2287-8. doi: 10.1128/AAC.34.11.2287.
2
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.
Antimicrob Agents Chemother. 1996 Mar;40(3):807-8. doi: 10.1128/AAC.40.3.807.
3
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Antimicrob Agents Chemother. 1998 Jul;42(7):1868. doi: 10.1128/AAC.42.7.1868.
4
In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis.
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:47-9. doi: 10.1093/jac/45.suppl_3.47.
5
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins.
Antimicrob Agents Chemother. 1990 Jul;34(7):1442-3. doi: 10.1128/AAC.34.7.1442.
6
Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs.
Diagn Microbiol Infect Dis. 1987 Oct;8(2):131-3. doi: 10.1016/0732-8893(87)90162-3.
7
8
Activity of nine fluoroquinolones against strains of Bordetella bronchiseptica.
Int J Antimicrob Agents. 1999 Aug;12(4):355-8. doi: 10.1016/s0924-8579(99)00077-1.
9
Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.
Antimicrob Agents Chemother. 1989 Apr;33(4):591-2. doi: 10.1128/AAC.33.4.591.
10
In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
Chemotherapy. 1998 Mar-Apr;44(2):77-84. doi: 10.1159/000007096.
引用本文的文献
1
State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.
Infection. 1998 Jul-Aug;26(4):242-6. doi: 10.1007/BF02962373.
2
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Antimicrob Agents Chemother. 1998 Jul;42(7):1868. doi: 10.1128/AAC.42.7.1868.
3
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.
Antimicrob Agents Chemother. 1996 Mar;40(3):807-8. doi: 10.1128/AAC.40.3.807.
4
Update of epidemiology, diagnosis, and treatment of pertussis.
Eur J Clin Microbiol Infect Dis. 1996 Mar;15(3):189-93. doi: 10.1007/BF01591352.
5
Comparison of media for agar dilution susceptibility testing of Bordetella pertussis and Bordetella parapertussis.
Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):775-9. doi: 10.1007/BF01690992.
6
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
7
Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1991 Dec;42(6):1018-60. doi: 10.2165/00003495-199142060-00009.
本文引用的文献
1
Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:3-17. doi: 10.1093/jac/22.supplement_d.3.
2
Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project.
Antimicrob Agents Chemother. 1988 Jan;32(1):137-40. doi: 10.1128/AAC.32.1.137.
3
Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs.
Diagn Microbiol Infect Dis. 1987 Oct;8(2):131-3. doi: 10.1016/0732-8893(87)90162-3.
4
Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):65S-76S. doi: 10.1016/0732-8893(89)90069-2.
5
In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative.
Antimicrob Agents Chemother. 1989 Aug;33(8):1144-52. doi: 10.1128/AAC.33.8.1144.
6
Use of quinolones in pediatric patients.
Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S1113-6. doi: 10.1093/clinids/11.supplement_5.s1113.
7
Tissue penetration of the new quinolones in humans.
Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S1046-57. doi: 10.1093/clinids/11.supplement_5.s1046.
8
Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.
Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):653-4. doi: 10.1007/BF01968151.
9
Potential role of fluoroquinolones in pediatric infections.
Rev Infect Dis. 1989 Nov-Dec;11(6):878-89. doi: 10.1093/clinids/11.6.878.
10
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins.
Antimicrob Agents Chemother. 1990 Jul;34(7):1442-3. doi: 10.1128/AAC.34.7.1442.
Zotero 插件